⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30986169 | 0.75 | KDM4E (0.31) | — | |
| SCHEMBL22090550 | 0.74 | CYP2D6 (0.33) | — | |
| SCHEMBL30986162 | 0.73 | — | — | |
| SCHEMBL30715318 | 0.68 | HSD17B10 (0.39) | — | |
| SCHEMBL22090571 | 0.68 | — | — | |
| SCHEMBL22090141 | 0.68 | OPRM1 (0.30) | — | |
| SCHEMBL7351993 | 0.68 | — | — | |
| SCHEMBL30986160 | 0.67 | DRD4 (0.31) | — | |
| SCHEMBL18458998 | 0.67 | CYP2D6 (0.32) | — | |
| SCHEMBL30986155 | 0.67 | NEK2 (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113412113-B | Amino oxazinamides | 豪夫迈·罗氏有限公司 | 2024-07-26 | — | — | CN | claimed |
| CN-113412113-B | Amino oxazinamides | 豪夫迈·罗氏有限公司 | 2024-07-26 | — | — | CN | disclosed |
| US-20210363152-A1 | AMINOAZINE AMIDES | HOFFMANN LA ROCHE (US) | 2021-11-25 | — | — | US | disclosed |
| EP-3873473-A1 | AMINOAZINE AMIDES | F. Hoffmann-La Roche AG (CH) | 2021-09-08 | — | — | EP | disclosed |
| WO-2020123426-A1 | AMINOAZINE AMIDES | F. HOFFMANN-LA ROCHE AG (CH) | 2020-06-18 | — | — | WO | disclosed |
| WO-2020119896-A1 | HETEROCYCLIC INHIBITORS OF ATX | F. HOFFMANN-LA ROCHE AG (CH) | 2020-06-18 | — | — | WO | disclosed |
| US-20160250246-A1 | ORAL FORMULATIONS OF CYTIDINE ANALOGS AND METHODS OF USE THEREOF | CELGENE CORP (US) | 2016-09-01 | — | — | US | disclosed |